The estimated Net Worth of Advisors Llc Orbi Med Capit... is at least $3.75 Million dollars as of 3 September 2021. Advisors Capit owns over 8,084 units of Kinnate Biopharma stock worth over $254,904 and over the last 4 years Advisors sold KNTE stock worth over $3,496,519.
Sign up
Advisors Capit KNTE stock SEC Form 4 insiders trading
Advisors has made over 9 trades of the Kinnate Biopharma stock since 2020, according to the Form 4 filled with the SEC. Most recently Advisors sold 8,084 units of KNTE stock worth $274,775 on 3 September 2021.
The largest trade Advisors's ever made was buying 1,666,666 units of Kinnate Biopharma stock on 16 July 2021 worth over $9,999,996. On average, Advisors trades about 465,714 units every 49 days since 2020. As of 3 September 2021 Advisors still owns at least 96,190 units of Kinnate Biopharma stock.
You can see the complete history of Advisors Capit stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Insiders trading at Kinnate Biopharma
Over the last 4 years, insiders at Kinnate Biopharma have traded over $0 worth of Kinnate Biopharma stock and bought 12,223,600 units worth $79,803,534 . The most active insiders traders include Carl L Gordon, Advisors Llc Orbi Med Capit..., and Helen Sabzevari. On average, Kinnate Biopharma executives and independent directors trade stock every 74 days with the average trade being worth of $2,699,377. The most recent stock trade was executed by James B. Tananbaum on 8 May 2023, trading 1,780,000 units of KNTE stock currently worth $4,984,000.
What does Kinnate Biopharma do?
Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; KIN-3248 small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors FGFR2 and FGFR3 genes; and small molecule research programs, including Cyclin-Dependent Kinase 12(CDK12) inhibitor in its KIN004 program. The company was incorporated in 2018 and is headquartered in San Francisco, California. Kinnate Biopharma Inc. is a former subsidiary of Fount Therapeutics, LLC.
What does Kinnate Biopharma's logo look like?
Complete history of Advisors Capit stock trades at Imara Inc, Repare Therapeutics, Fusion Pharmaceuticals, and Kinnate Biopharma
Kinnate Biopharma executives and stock owners
Kinnate Biopharma executives and other stock owners filed with the SEC include:
-
Nima Farzan M.B.A.,
Pres, CEO & Director -
Mark A. Meltz,
COO, Gen. Counsel, Treasurer & Sec. -
Neha Krishnamohan,
CFO, Principal Accounting Officer and Exec. VP of Corp. Devel. -
Dr. Eric Anthony Murphy Ph.D.,
Chief Scientific Officer -
Jason Hampson M.D.,
VP and Head of Regulatory Affairs & Quality -
Priyanka Shah,
VP of Investor Relations & Communications -
Ken Kobayashi M.D.,
Sr. VP of Clinical Devel. -
Jason Hampson,
VP & Head of Regulatory Affairs -
Barbara Warren,
VP of People & Culture -
Eric Martin Ph.D.,
Sr. VP of Translational Medicine -
Dr. Robert Kania Ph.D.,
Sr. VP of Drug Discovery -
Dr. Richard Thomas Williams MBBS, Ph.D.,
Chief Medical Officer -
Nima Farzan,
Pres, CEO & Director -
Capital Management Iv, Llc ...,
-
Eric Anthony Murphy,
Chief Scientific Officer -
Helen Sabzevari,
-
Alsup Laurie Smaldone,
-
James B. Tananbaum,
-
Dean J Mitchell,
-
Keith T. Flaherty,
-
Advisors Llc Orbi Med Capit...,
-
Advisors Llc Orbi Med Capit...,
-
Michael E Rome,
-
Melissa B, Epperly,
-
Carl L Gordon,
Director -
Capital Management Iv, Llc ...,
-
Advisors Llc Orbi Med Capit...,
-
Jill De Simone,
-
Neha Krishnamohan,
CHIEF FINANCIAL OFFICER -
Mark A Meltz,
COO GENERAL COUNSEL SECRETARY -
Richard Thomas Williams,
CHIEF MEDICAL OFFICER -
Nima Farzan,
CHIEF EXECUTIVE OFFICER